Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 2
2017 2
2018 6
2019 5
2020 3
2021 3
2022 2
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
Clinical outcomes in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma after second-line salvage chemotherapy: A retrospective study.
Yagi Y, Kanemasa Y, Sasaki Y, Sei M, Matsuo T, Ishimine K, Hayashi Y, Mino M, Ohigashi A, Morita Y, Tamura T, Nakamura S, Okuya T, Shimizuguchi T, Shingai N, Toya T, Shimizu H, Najima Y, Kobayashi T, Haraguchi K, Doki N, Okuyama Y, Shimoyama T. Yagi Y, et al. Among authors: shimizuguchi t. Cancer Med. 2023 Sep;12(17):17808-17821. doi: 10.1002/cam4.6412. Epub 2023 Aug 28. Cancer Med. 2023. PMID: 37635630 Free PMC article.
[Polatuzumab vedotin, bendamustine, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma, including the outcome as a bridging treatment to CAR-T cell therapy or allogeneic hematopoietic stem cell transplant].
Morita Y, Yagi Y, Kanemasa Y, Sasaki Y, Ishimine K, Hayashi Y, Mino M, Ohigashi A, Tamura T, Nakamura S, Okuya T, Shimizuguchi T, Shingai N, Toya T, Shimizu H, Najima Y, Kobayashi T, Haraguchi K, Doki N, Okuyama Y, Ohashi K, Shimoyama T. Morita Y, et al. Among authors: shimizuguchi t. Rinsho Ketsueki. 2023;64(7):586-595. doi: 10.11406/rinketsu.64.586. Rinsho Ketsueki. 2023. PMID: 37544717 Japanese.
Multicenter retrospective study of stereotactic body radiotherapy for patients with previously untreated initial small hepatocellular carcinoma.
Doi Y, Nagata Y, Matsumoto Y, Numata K, Sasaki R, Yamada T, Igaki H, Imagumbai T, Katoh N, Yoshitake T, Shimizuguchi T, Fujioka D, Inoue M, Koide Y, Kimura T, Ito Y. Doi Y, et al. Among authors: shimizuguchi t. Hepatol Res. 2023 Aug;53(8):749-760. doi: 10.1111/hepr.13908. Epub 2023 Apr 25. Hepatol Res. 2023. PMID: 37036153
Radiation therapy and the risk of herpes zoster in patients with cancer.
Shimizuguchi T, Sekiya N, Hara K, Taguchi A, Nakajima Y, Miyake Y, Shibata Y, Taguchi K, Ogawa H, Ito K, Karasawa K. Shimizuguchi T, et al. Cancer. 2020 Aug 1;126(15):3552-3559. doi: 10.1002/cncr.32926. Epub 2020 May 15. Cancer. 2020. PMID: 32412661 Free article.
Combination Therapy for a Severe Axillary Keloid with Abscesses: A Case Report.
Dohi T, Cho H, Kamegai M, Fukumitsu K, Shimizuguchi T, Hayakawa S, Karasawa K, Ogawa R. Dohi T, et al. Among authors: shimizuguchi t. J Nippon Med Sch. 2023 Feb 1;89(6):645-648. doi: 10.1272/jnms.JNMS.2022_89-610. Epub 2021 Nov 26. J Nippon Med Sch. 2023. PMID: 34840224 Free article.
[Tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma: real-world data from single institute experience].
Yagi Y, Kanemasa Y, Sasaki Y, Hayashi Y, Mino M, Kato C, Sakai S, Ohigashi A, Kanbara Y, Morita Y, Tamura T, Atsuta Y, Konuma R, Nakamura S, Wada A, Okuya T, Kageyama A, Murakami D, Nakashima S, Uchibori Y, Onai D, Hamamura A, Nishijima A, Omuro Y, Shingai N, Shimizuguchi T, Toya T, Shimizu H, Najima Y, Kobayashi T, Haraguchi K, Ohashi K, Doki N, Okuyama Y, Shimoyama T. Yagi Y, et al. Among authors: shimizuguchi t. Rinsho Ketsueki. 2022;63(10):1363-1372. doi: 10.11406/rinketsu.63.1363. Rinsho Ketsueki. 2022. PMID: 36351641 Japanese.
24 results